HUTCHMED (LON:HCM) Hits New 52-Week Low – Time to Sell?

HUTCHMED (China) Limited (LON:HCM) shares hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as GBX 186 and last traded at GBX 188.50, with a volume of 127305 shares changing hands. The stock had previously closed at GBX 193.

HUTCHMED Stock Performance

The firm’s 50 day moving average price is GBX 209.73 and its two-hundred day moving average price is GBX 214.58. The company has a debt-to-equity ratio of 7.91, a quick ratio of 2.97 and a current ratio of 4.96. The firm has a market cap of £1.62 billion, a PE ratio of 3.56 and a beta of 0.45.

About HUTCHMED

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S.

We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China.

HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange’s AIM market (Nasdaq/AIM:HCM; HKEX:13).